News

The survival rate of patients with recurrent or treatment-refractory pancreatic cancer was improved when patients were treated with a combination of ruxolitinib and capecitabine.

Pazopanib was better tolerated with noninferior efficacy when compared to sunitinib as a treatment for patients with advanced renal cell carcinoma.

A study shows that a new chemoresponse assay improves the overall survival and progression-free survival of patients with recurrent ovarian cancer while helping clinicians individualize care for those patients.

Breast cancer pathogenesis may be driven by activation of steroid hormone receptors, like those for estrogen and progesterone, and may also be driven by receptor tyrosine kinases.

The investigational immunotherapy Allovectin (velimogene aliplasmid) failed to meet key endpoints in a phase III trial in patients with stage III/IV metastatic melanoma.

Necitumumab plus chemotherapy as a first-line therapy for patients with metastatic squamous NSCLC demonstrated an improvement in OS vs chemotherapy alone.

Nintedanib (also known as Vargatef and BIBF 1120) is an oxindole-based, orally-available triple kinase inhibitor targeting the angiogenesis factors VEGF, PDGF, and FGF.

The week of August 5 in review, featuring articles and physician interviews on tamoxifen in BRCA-positive patients, advances in melanoma, and the MAGE-A3 protein in lung cancer.

Tamoxifen significantly lowered the risk of contralateral or secondary breast cancer by more than half in patients with BRCA1/2 mutations.

The week of July 29 in review, featuring stories and physician interviews on genetic testing, expanding anti-HER2 therapy, and nivolumab for the treatment of melanoma.

Afatinib is an FDA-approved pan-HER inhibitor for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

The week of July 22 in review, featuring stories and physician interviews on crizotinib in NSCLC, the G-200 vaccine for glioblastoma, and ibrutinib in non-Hodgkin lymphoma.

Studies have confirmed that dysregulation of apoptosis is implicated in the pathogenesis of many diseases. Deficient apoptosis is key in the development of cancer.

Researchers at the NCI have developed the most comprehensive analysis of coding variants in the most frequently studied human tumor cell lines in cancer research.

The risk of developing ovarian cancer has been linked to several factors including family history, age, and pregnancy history. In the U.S., ovarian cancer accounts for 3% of all cancer in women.

The FDA has approved the pan-HER inhibitor afatinib (Gilotrif), along with a companion diagnostic, to treat patients with metastatic NSCLC who express specific types of EGFR mutations.

The week of July 8 in review, featuring clinical articles and videos on targeting the PI3K and AKT pathways, ASCO's CancerLinQ program, and ibrutinib in CLL and MCL.

A phase III study of Revlimid in combination with dexamethasone in patients with newly diagnosed multiple myeloma met its primary endpoint of PFS.

The FDA has received a new drug application for ibrutinib as a therapy for previously treated CLL and previously treated MCL.

If approved, this regimen would be the first neoadjuvant regimen ever approved for the treatment of cancer.

Learn how Genentech researchers Shiva Malek and Georgia Hatzivassiliou worked together to solve a mystery and change cancer research.

The mechanism of action of trastuzumab (Herceptin), a monoclonal antibody that is approved for the treatment of early-stage breast cancer that is HER2-positive.

The week of June 24 in review, featuring clinical articles and physician interviews on an FDA approval, crizotinib in NSCLC, sorafenib in DTC, and more.

The FDA approved an update to the product labeling for dasatinib (Sprycel), Bristol-Myers Squibb Company and Otsuka America Pharmaceutical announced on June 20.

Patients with chronic lymphocytic leukemia (CLL) and patients with mantle cell lymphoma (MCL) showed high response rates to therapy with ibrutinib.

In advance of the 2013 ASCO Annual Meeting, Targeted Healthcare spoke with Mike Thompson, MD, PhD, about the use of social media in the field of oncology.

Elotuzumab in combination with lenalidomide and low-dose dexamethasone showed efficacy in patients with previously treated multiple myeloma.

The week of June 10 in review, featuring stories and videos on testing for BRCA1/2, bevacizumab in cervical cancer, gene patenting, MPDL3280A in lung cancer, and more.